Clinical Trials Browser

Recurrence × durvalumab × Head & Neck × Clear all

NCT03723967 2024-04-22

FRAIL-IMMUNE

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT03799744 2022-03-28

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Phase 1 Unknown

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT02369874 2021-02-10

EAGLE

Phase 3 Completed

736 enrolled 26 charts

Head and Neck Neoplasms, Recurrence

NCT02207530 2020-09-29

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

112 enrolled 20 charts

Head and Neck Neoplasms, Recurrence

NCT02319044 2020-09-29

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

267 enrolled 27 charts

Head and Neck Neoplasms, Recurrence